Vip-Z provides a single solution to problems encountered due to iron-deficiency anaemia which has a dual advantage of building blood and foetal cells with simultaneous protection from oxidative free radical stress.
Addressing a press conference at the launch of VIP-Z, Koteswara Rao, managing director, Vanguard Therepeutics, said that VIP-Z contains Carbonyl iron, given in timed release dosage system to deliver directly into duodenum where there is maximum absortion of iron takes place without any gastric upset. The product is targeted for iron deficiency anaemia which is found to be very common among pregnant women.
Since iron deficiency leads to many congenial defects during pregnancy, this product when administered, in appropriate dosages, will treat effectively for anaemic cases, particularly women, he said. Later, describing the industry which is marching towards launch of newer molecules by many pharmceutical companies post 2005, the company also has started groundwork by collaborating with research institutions to seek their guidance and implement latest technologies for developing new products.